Diagnosing anemia in inflammatory bowel disease: Beyond the established markers  by Oustamanolakis, Pantelis et al.
ava i l ab l e a t www.sc i enced i r ec t . com
Journal of Crohn's and Colitis (2011) 5, 381–391REVIEW ARTICLE
Diagnosing anemia in inflammatory bowel disease:
Beyond the established markers
Pantelis Oustamanolakis, Ioannis E. Koutroubakis⁎, Elias A. KouroumalisDepartment of Gastroenterology, University Hospital of Heraklion, Crete GreeceReceived 5 February 2011; received in revised form 16 March 2011; accepted 16 March 2011⁎ Corresponding author at: Dept of Ga
2810392253, fax +30 2810542085.
E-mail address: ikoutroub@med.uo
1873-9946/$ - see front matter © 201
doi:10.1016/j.crohns.2011.03.010KEYWORDS:
Anemia;
Crohn's disease;
Ferritin;
Iron;
Iron deficiency;
Ulcerative colitis
Abstract
The main types of anemia in inflammatory bowel disease (IBD) are iron deficiency anemia (IDA)
and anemia of inflammatory etiology, or anemia of chronic disease (ACD). In the management of
IBD patients with anemia it is essential for the physician to diagnose the type of anemia in order
to decide in an evidence-based manner for the appropriate treatment. However, the assessment
of iron status in IBD in many cases is rather difficult due to coexistent inflammation. For this
assessment several indices and markers have been suggested. Ferritin, seems to play a central
role in the definition and diagnosis of anemia in IBD and transferrin, transferrin saturation (Tsat),
and soluble transferrin receptors are also valuable markers. All these biochemical markers have
several limitations because they are not consistently reliable indices, since they are influenced
by factors other than changes in iron balance. In this review, in addition to them, we discuss the
newer alternative markers for iron status that may be useful when serum ferritin and Tsat are not
sufficient. The iron metabolism regulators, hepcidin and prohepcidin, are still under
investigation in IBD. Erythrocytes parameters like the red cell distribution width (RDW) and
the percentage of hypochromic red cells as well as reticulocyte parameters such as hemoglobin
concentration of reticulocytes, red blood cell size factor and reticulocyte distribution width
could be useful markers for the evaluation of anemia in IBD.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.stroenterology, University Hos
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Figure 1 Etiology of anemia in inflammatory bowel disease.1. Introduction
Anemia is the most frequent extraintestinal manifestation of
inflammatory bowel disease (IBD) with a great impact on the
patients' quality of life.1 For this reason the research has
recently been focused on the pathophysiology, diagnosis and
treatment of anemia in IBD. Several studies have contributed
in this field unraveling its main mechanisms and suggesting
new diagnostic criteria.2–4 At the same time, new therapeu-
tic methods were developed, especially in the field of iron
and erythropoietin supplementation therapy.5–10 Nowadays,
the diagnosis and therapy of anemia has become one of the
most challenging fields in the clinical IBD practice.
The prevalence of anemia in IBD varies between 15% and
75%, depending on the definition and subgroup of patients
examined.11 Patients present with a variety of symptoms and
signs, such as fatigue, weakness, paleness, headaches,
dyspnea, tachycardia, reduced functionality of the muscu-
loskeletal system and impaired cognitive functions.12,13
These symptoms may occur before the establishment of
anemia in the full blood count and the clinicians should
detect and treat them early, in order to prevent patient's
hospitalization or prolongation of hospital stay. On the other
hand, the economic burden of anemia in IBD is very
important, on the basis of reducing patient's ability to work
and often leading to prolonged hospitalization.
The main types of anemia in IBD are iron deficiency anemia
(IDA) and anemia of inflammatory etiology, or anemia of
chronic disease (ACD) (Fig. 1). IDA, which is the most common,
is the result of reduced iron uptake from the enterocyte and
chronic blood loss from the gastrointestinal tract, due to
chronic inflammation of the epithelium of the small and large
intestine. On the other hand, inflammation, through an
inflammatory cytokines-mediated mechanism, leads to a
decreased iron level in the circulation and thus to a limited
availability of iron for erythroid cells. Besides that, inflamma-
tory mechanisms also lead to decreased iron uptake from the
intestinal epithelium, thus providing a very complex two-wayinteractive pathophysiologic pathway between iron deficiency
(ID) mechanisms and inflammation.4
In the management of IBD patients with anemia it is
essential for the physician to diagnose the type of anemia
and to determine the degree of iron deficiency and the
degree of inflammation in each patient, in order to decide in
an evidence-based manner for the treatment. In our
armamentarium nowadays there are plenty of established
and new generation indices and markers (Table 1), some of
them being a product of latest new technology blood
analyzers. There is a growing volume of data about the
ability of such markers to differentiate between ID and
inflammation, in order to diagnose easily and with a cost-
effective way the type of anemia in IBD.
This review discusses the role of established and new
indices and markers in the diagnosis of anemia in patients
with IBD.
Table 1 Markers that differentiate iron deficiency anemia
from anemia of chronic disease in inflammatory bowel
disease.
Parameter Iron
deficiency
anemia
Anemia of
chronic
disease
Mixed
anemia
Ferritin Reduced Increased or
normal
Normal or
increased
Transferrin Increased Reduced or
normal
Reduced
Tsat Reduced Reduced Reduced
sTfR Increased Normal or
reduced
Normal or
increased
sTFR-F
index
Increased Reduced Increased
Hepcidin Reduced Increased Increased or
reduced
MCV Reduced Reduced or
normal
Reduced or
normal
CRP Normal Increased Increased
RDW Increased Normal or
increased
Normal or
increased
CHr Reduced Reduced Reduced
RSF Reduced Normal or
reduced
Normal or
reduced
RDWR Increased Normal or
increased
Normal or
increased
Tsat, Transferrin saturation; sTfR, soluble transferrin receptor;
sTFR-F, soluble transferrin receptor-ferritin;MCV,Mean corpuscular
volume; CRP, C-reactive protein; RDW, red cell distribution width;
RSF, Red blood cell size factor; and RDWR, Reticulocyte distribution
width.
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2.1. Serum iron concentration
Iron is an essential element employing by almost all types of
cells as a cofactor for fundamental biochemical reactions or
as a part of numerous enzymes participating in redox
reactions, oxygen transport, energy metabolism and DNA
synthesis. Iron possesses a very flexible coordination
chemistry and redox reactivity, which enable it to interfere
with proteins, bind to oxygen, transfer electrons or mediate
catalytic reactions.
The content of iron in the human body is normally 3–4 g,
corresponding to a concentration of 40–50 mg of iron/kg body
weight. About 60% of the iron is present in the form of
hemoglobin in the circulating red blood cells and another
6–7 mg/kg in the form of myoglobin and haem and
nonhaem enzymes. Transport iron, bound to the transport
protein transferrin, represents only a tiny part (b0.2%) of total
body iron. The iron bound to transferrin, supplies the tissues
with the iron which they need. The remaining iron (15–30% of
the total iron) is bound in a storage form, principally in the
cytoplasm in the form of ferritin but also in lysosomes, as
hemosiderin.14
Serum iron concentrations reflect the balance between
the flow of iron into and out of the plasma pool. Iron in this
pool turns over very rapidly and plasma iron levels aresubject to large and rapid changes. The iron stores show
extensive fluctuations dependent on such factors as circadi-
an rhythm, turnover of the iron in the major iron
compartments and absorption. The turnover of serum iron
takes place many times daily.15,16 The measurement of
serum iron concentration is subject to many variables that
may introduce substantial errors into results, such as
inadequately processed glassware, contamination of re-
agents with small amounts of iron, turbidity, and entrapment
of iron in plasma proteins during their precipitation.17
Moreover, many factors such as menstrual bleeding in
women,18,19 acute or chronic inflammatory processes (in-
cluding IBD),20,21 malignancy,22 chemotherapy and myocar-
dial infarction23,24 may influence the measured values. In
conclusion, serum iron concentration is a rather unreliable
index for the evaluation of IDA in IBD patients.2.2. Ferritin
Ferritin is an oligomeric protein characterized by a hollow
protein shell capable to store substantial amounts of iron in a
non-toxic, soluble and bioavailable form. It serves as a
reservoir of iron for cellular requirements for almost all
human cells. The main storage sites of ferritin are liver,
spleen and skeletal muscle. The origin of serum ferritin is not
well established, although animal studies suggest that it is
mostly derived from liver.25
Measurement of ferritin provides a useful indirect
estimate of body iron stores. Small amounts of ferritin
secreted into the circulation can be measured by immuno-
assay. In healthy individuals serum ferritin levels correlate
with body iron stores. The maximum possible concentration
of serum ferritin (in glycosylated form) derived from active
ferritin synthesis is considered to be about 4000 μg/L. Higher
concentrations are thought to be due to the release of
intracellular ferritin from damaged cells.26
In the healthy population elevated ferritin concentrations
usually indicate increased iron stores, but a number of
disorders may also increase serum ferritin levels indepen-
dently of the body iron. Serum ferritin is an acute phase
reactant and conditions such as fever, acute infections,
chronic inflammatory disorders (including IBD), may increase
the serum ferritin concentration.26 Acute and chronic
damage to the liver, as well as damage to other tissues,
may increase serum ferritin as part of an inflammatory
process or by release of tissue ferritin (not glycosylated)
from damaged parenchymal cells. Defective clearance of
circulating ferritin, for example due to liver dysfunction,
may also lead to elevation of the serum ferritin concentra-
tion. Malignant diseases and chemotherapy may increase
serum ferritin levels.26 These factors may result in increased
serum ferritin levels, which may obscure iron deficiency and
complicate the detection of iron overload. On the other
hand, conditions that lower the serum ferritin levels without
ID are hypothyroidism and vitamin C deficiency.26
Every μg/L of serum ferritin corresponds to 8–10 mg
storage of iron.27 Guyatt et al. in an analysis of 55 studies
reported that the mean area of the receiver–operator
characteristic (ROC) curves for ferritin was 0.95, while that
of MCV was only 0.76 in the diagnosis of ID.28 A ferritin level
of ≤12 μg/L has a high specificity (98%) but low sensitivity
384 P. Oustamanolakis et al.(25%) for diagnosis of ID.29 The sensitivity can be improved to
92% with the same specificity of 98% if a cut-off ferritin level
of 30 μg/L is used. Kis et al.30 in patients who had undergone
bone marrow aspirations, found that a ferritin of ≤100 μg/L
had a 64.9% sensitivity and a 96.1% specificity for diagnosis of
ID. The threshold for ferritin of 100 μg/L was also found to
stratify anemic veterans into a high-risk group for advanced
colonic neoplasia from a low-risk non-anemic group.31 Based
on these data, a simple clinical cutoff can guide management
of anemic subjects: serum ferritin b15 μg/L indicates ID,
while serum ferritin N100 μg/L mostly excludes IDA; inter-
mediate values warrant further investigation.28 Although
ferritin level increases with age, and is an acute-phase
reactant influenced by chronic inflammation, infection,
malignancy and chronic renal failure, the sensitivity and
specificity of the serum ferritin is little changed if the
100 μg/L threshold is used.28,30 Others have proposed that a
ferritin level of 70 μg/L was the necessary safety limit for
exclusion of ID.32,33 Guagnozzi et al.34 in a study with 76 IBD
patients found that the sensitivity and specificity of ferritin,
with a cutoff value of 15 ng/mL, were low (89% and 64.5%,
respectively) for diagnosis of ID. ROC analysis demonstrated
that ferritin diagnostic accuracy could be improved by using
higher cutoff values. In anemic IBD patients, the ferritin
cutoff value of 28 ng/mL showed a sensitivity of 93.8% and a
specificity of 90%, indicating that ferritin may be proposed as
an accurate, simple, and useful marker to identify ID,
particularly in anemic IBD patients.
According to the established guidelines on the diagnosis
and management of IDA and anemia in IBD,35 serum ferritin is
included in the screening parameters for anemia, with the
recommendation to be measured every 6 to 12 months, in
patients in remission or mild disease, or at least every
3 months in outpatients with active disease. Ferritin was
added to other parameters (full blood count and CRP) as
minimum requirements to diagnose anemia, inflammatory
flare or IDA in an early stage, because IDA is a very common
nutritional deficiency with a strong impact on anemia.36
Ferritin, along with Tsat and CRP, is the minimum workup for
anemic patients with IBD. The combination of serum ferritin
levels with soluble transferrin receptors (sTfR) levels can be
used to detect ID (increased sTfR, low ferritin), inflammation
(normal sTfR and ferritin) or mixed conditions (increased
sTfR, normal ferritin). Furthermore, ferritin b30 μg/L (in
combination with Tsat b16%) is an established index for ID in
patients without evidence of inflammation. In the presence
of inflammation, the lower limit of serum ferritin consistent
with normal iron stores is considered to be 100 μg/L, thus the
diagnostic criteria for ACD are a serum ferritin N100 μg/L and
Tsat b16%. If the serum ferritin level is between 30 and
100 μg/L, a combination of true IDA and ACD is likely. Finally,
serum ferritin can be used in the form of the sTfR/log ferritin
ratio as a useful tool to exclude ID, when it is b1.372.3. Transferrin/total iron binding capacity
Transferrin (TRF) mediates iron exchange between body
tissues, taking iron from donor sites, such as the gut and
macrophages, to acceptor cells like erythroblasts. In
conditions of normal iron status, serum TRF is saturated to
about one-third of its iron-binding capacity, so that we havea mixture of apotransferrin, the two mono-ferric forms and
di-ferric TRF. TRF is mainly synthesized in liver hepatocytes
and in small amounts in brain, lymph nodes, testicular tissue
and mammary glands.38
Serum TRF is an indicator for ID but is not as useful as the
serum ferritin level. TRF concentrations increase when iron
stores are depleted and decrease with iron overload.
However, the TRF level is not a consistently reliable index,
since it is influenced by factors other than changes in iron
balance. Inflammation, infection, malignancy, liver disease,
nephrotic syndrome and malnutrition may all reduce the
serum TRF concentration, while pregnancy and oral contra-
ceptives will increase it.26
Total iron binding capacity (TIBC) indicates the maximum
amount of iron needed to saturate plasma or serum TRF. The
correlation between TIBC and TRF is generally considered
good, but they also present important differences. Although
TIBC is cheaper, there are several advantages of serum TRF.
Due to binding of iron to other plasma proteins (mainly
albumin), TIBC methods generally overestimate the iron
binding capacity of transferring and no generic reference
values are available. In contrast, internationally accepted
interim reference ranges are available for serum TRF. In view
of these observations, determination of TRF concentration,
rather than TIBC, is recommended. However, TIBC measure-
ments may be preferred in populations with genetic variation
of TRF.39
Although serum ferritin measurement is the investigation
of choice in ID, many laboratories continue to measure iron
and TIBC/TRF. In a recent study, Hawkins et al. comparing
the diagnostic utility of iron, TRF and Tsat measurements in
the diagnosis of ID across inpatient and outpatient found that
TRF or TIBC measurement outperformed iron measurement
and saturation index.40 Shek et al.,41 in a more cost effective
approach to the diagnosis of ID, suggested that serum iron
and TIBC should be done first, and serum ferritin is not
required when Tsat b16% and TIBC N70 mmol/L or if Tsat is
≥22% and TIBC ≤70 mmol/L. A study from Germany42
investigating the diagnostic validity of an increased TRF
concentration for diagnosis of ID showed diagnostic sensitiv-
ity 36% and specificity 97%. Finally, a recent study on
rheumatoid arthritis showed limited value of TIBC in the
diagnosis of ID.43
In conclusion, it seems that TRF/TIBC test is superior to
serum iron or Tsat, but is not better than ferritin in diagnosis
of ID. In any way, TRF/TIBC should be used with conscious-
ness and only in parallel with other iron status tests, in order
to get the highest diagnostic yield. In IBD patients, TRF has
been suggested to be included, among other parameters, in
the more extensive workup of anemia, when the minimum
investigation (ferritin, Tsat, and CRP) cannot identify the
cause of anemia.35 In addition, TRF levels can be used, in
combination with other indices (serum erythropoietin and
sTfR), to predict cases that will not respond to intravenous
iron alone and may profit from a combination therapy with
erythropoiesis stimulating agents.442.4. Transferrin saturation
Transferrin saturation (Tsat) is an index reported as a
percentage and is the quotient of iron levels (μmol/L)/TRF
385Diagnosing anemia in inflammatory bowel diseaselevels (mg/dl) in the serum or plasma multiplied by 70.9
(fasting blood sample).45 Tsat is a measurement of the iron
content of the circulating TRF. Normally, there is enough TRF
present in 100 mL serum to bind 250 to 450 μg (4.4 to
8.0 μmol) of iron. Since the normal iron levels are about
1.8 μmol/dl (100 μg/dl), TRF is roughly one-third saturated
with iron. TRF is normally 20 to 50% saturated with iron. A
normal value for Tsat often accompanies low serum iron
levels in the ACD. However, exceptions are so common as to
considerably detract from the diagnostic value of measuring
Tsat.17
A Tsat b16% implies a suboptimal supply of iron for
erythropoiesis. A reduced Tsat has a relatively high sensitiv-
ity (90%) but a relatively low specificity (40–50%) for
detecting ID.46 Determination of Tsat gives only an indirect
indication of the extent of iron use in the bone marrow and
does not provide any information about the condition of the
iron stores. As Tsat is subject to certain circadian fluctua-
tions, its measurement should always be carried out at the
same time of the day and repeated several times.45 Tsat also
has some acute-phase reactivity as TRF may be elevated in
the setting of inflammation, which would lower the Tsat, if
circulating iron is constant. Decreased TRF synthesis in the
setting of malnutrition and chronic disease results in a raised
Tsat.46
Three studies47–49 examining the use of Tsat in renal
failure patients, with cutoff values between 19 and 21%,
showed sensitivity 59–88% and specificity 63–78% in diagno-
sis of ID, suggesting that only a few patients with true ID have
a Tsat N20%.46 In the guidelines for diagnosis of anemia in
IBD, Tsat is included in the minimum anemia workup, along
with ferritin and CRP. It is used, in combination with ferritin,
at a lower cutoff point (Tsat b16%) in the diagnostic criteria
for IDA (when ferritin is b30 μg/L) or for ACD (when ferritin is
N100 μg/L). A Tsat level between 16 and 50% indicates
adequate iron stores, while a value N50% is consistent with a
potential iron overload.352.5. Soluble transferrin receptors
Serum iron, in the form of diferric TRF, is delivered to cells
via the TRF-to-cell cycle, which involves the transferrin
receptor (TfR1), a disulfide-linked homodimer composed of
two identical glycosylated subunits. Each of the subunits can
bind one diferric TRF molecule. The number of soluble
transferrin receptors (sTfR) reflects the cellular require-
ments for iron, and varies both as a function of the cell type,
and also with the cell's morphological development. Whereas
early normoblasts have some 300,000 TRF receptors, at the
peak period of haem synthesis, in the intermediate normo-
blast, this increases to around 800,000/cell. The circulating
receptor seems to be a truncated form of the cellular
receptor and it is bound to TRF.25
In ID the numbers of TfR increase significantly. Part of the
TfR is shed into the plasma, where the concentration can be
measured by immunoassay and used as an indicator of ID.
This assay seems particularly useful for diagnosis of ID in
patients with infection, inflammation or malignancy where
serum ferritin is not a good indicator of IDA.50 The
concentration of sTfRs in the serum is an indicator of the
iron supply available for erythropoiesis; sTfRs reflecterythropoiesis and inversely the amount of iron available
for erythropoiesis.45,51–53
Unlike ferritin and TRF, chronic inflammation and hepatic
damage have no effect on sTfRs, which should make them a
more reliable parameter than serum ferritin for diagnosing ID
in patients with IBD.45,46 However, Fernandez-Rodriguez et
al.54 found sTfRs to be less accurate than serum ferritin in
this setting. They demonstrated a sTfR sensitivity of 70% and
a specificity of 59% at a cutoff of 2.6 mg/L. Tessitore et al.48
demonstrated a sTfR sensitivity of 81% and a specificity of
71% at a cutoff of 1.5 mg/L. The sTfR:log ferritin ratio has
also been suggested as able to differentiate more accurately
between IDA and ACD or to assess the iron status in patients
with mixed type anemia.53 In another study of 176 patients
(51.1% with ACD and 48.8% with IDA),55 both the sensitivity
and specificity of sTfR in IDA was found to be 100%, whereas
in ACD, these were 66.6% and 100% respectively, concluding
that sTfR is a reliable index of IDA and could be useful in
distinguishing IDA from ACD. These findings are in agreement
with a more recent study56 where it was found that sTfR
levels can be very useful in differentiating pure IDA, ACD and
ACD with coexisting IDA, thus providing a noninvasive
alternative to bone marrow iron. A high diagnostic power
of sTfR or sTfR:log ferritin ratio for differentiating IDA from
ACD and mixed anemia has been suggested by several studies
in various groups of patients.37,57
Increased concentrations of sTfRs are reported in other
disorders of erythropoiesis, such as hemolytic anemia,
thalassemia and polycythemia, while they are reduced in
aplastic anemia and other conditions with hypoproliferative
erythropoiesis, such as renal anemia.45 Serum sTfR levels
average 5.0±1.0 mg/L in normal subjects but the various
commercial assays give disparate values because of the lack
of an international standard.52 The most important deter-
minant of sTfR levels appears to be marrow erythropoietic
activity which can cause variations up to 8 times below and
up to 20 times above average normal values. Measurements
of sTfR are very helpful to investigate the pathophysiology of
anemia, quantitatively evaluating the absolute rate of
erythropoiesis and the adequacy of marrow proliferative
capacity for any given degree of anemia, and to monitor the
erythropoietic response to various forms of therapy, in
particular allowing to predict response early when changes in
hemoglobin are not yet apparent.52 Conclusively, sTfR
represents a valuable quantitative assay of marrow erythro-
poietic activity as well as a marker of tissue ID, with the
restriction that the assay is not widely available and not
standardized, which impedes its clinical application.3. Iron metabolism regulators
3.1. Hepcidin
Hepcidin is a circulating peptide which plays a major role in
iron homeostasis. It is mainly produced in the liver as well as
by myeloid cells58 and by activated splenocytes,59 through a
precursor protein (prohepcidin). Hepcidin reduces the
quantity of circulating iron by preventing its exit from the
cells, especially from enterocytes and macrophages. It binds
to ferroportin, in order to limit iron egress, inducing its
internalization and degradation.60,61 In the absence of
Table 2 Studies evaluating hepcidin and prohepcidin in
inflammatory bowel disease.
Author
(reference)
Study design Disease (N)
HC (N)
Results
Semrin et al. 69 Urine
hepcidin
measurement
CD (19) Increased
levels in active
disease
positively
correlated
with IL-6 and
CRP
Arnold et al. 70 Serum
hepcidin
measurement
UC (51) CD
(10) HC
(25)
Decreased
levels
positively
correlated
with IL-6
Oustamanolakis
et al. 71
Serum
hepcidin
measurement
UC (49) CD
(51) HC
(102)
Increased
levels
positively
correlated
with ferritin
and disease
activity (for
UC)
Kaya et al. 76 Serum
prohepcidin
measurement
Pediatric
IBD (15)
Increased
levels
positively
correlated CRP
Nagy et al 77 Serum
prohepcidin
measurement
UC (72) CD
(30) HC
(28)
No significant
different
compared with
controls
Oustamanolakis
et al 71
Serum
prohepcidin
measurement
UC (49) CD
(51) HC
(102)
Decreased
levels not
correlated
with ferritin or
disease
activity
CD, Crohn's disease; UC, ulcerative colitis; HC, healthy controls;
CRP, C reactive protein; and IL-6, interleukin-6.
386 P. Oustamanolakis et al.hepcidin, increased intestinal iron absorption associated
with increased iron efflux from macrophage leads to
parenchymal iron overload.62,63
Hepcidin expression is controlled by iron and inflamma-
tion.64 The proinflammatory cytokines play a central role in
the induction of the hepcidin gene.65 IL6 stimulates hepcidin
expression in vivo with concomitant reduction in serum
iron.66,67 The characteristic features of ACD (reduction in
serum iron, retention of iron in macrophages and blocking of
intestinal iron absorption) are all compatible with the
consequences of an increase in the production of hepcidin.
Iron overload induces an increase in the synthesis of hepcidin
whereas IDA results in the reduction in the production of
hepcidin, thus ensuring a better availability of iron to the
developing erythrocytes in the bone marrow.68 Hypoxia also
inhibits the synthesis of hepcidin.65 It seems that hepcidin
appears as the “ferrostat” of the organism, adjusting the
quantities of circulating iron according to body requirements.
The literature about the role of hepcidin in the
mechanisms of anemia in IBD is limited69–71 and not very
clear with the results of the existing studies to be rather
conflicting (Table 2). In the study of our group71 the
sensitivity of low hepcidin for diagnosis of anemia was 71%
and the specificity was 43%. Similarly, the sensitivity of low
hepcidin for diagnosis of IDA was 81% and the specificity was
45%.
It is worth mentioning that currently there is no reference
method for hepcidin measurement. Hepcidin levels reported
by the various methods vary considerably but analytical
variance is generally low and similar for all methods.72
3.2. Prohepcidin
Prohepcidin is the 60 amino acid immature form of hepcidin.
Serum prohepcidin levels have controversial clinical signif-
icance since they have been found to be highly variable in
normal physiological conditions73 and without correlation
with the expected hepcidin responses to physiologically
relevant stimuli.74 Sasu et al.75 reported that prohepcidin
did not correlate with hepcidin or anemia of inflammation
and appears to be an unstable analyte in serum.
Research work on the role of prohepcidin in the anemia of
IBD patients is very limited71,76,77 (Table 2). In the study of
our group,71 median prohepcidin levels were significantly
lower in IBD patients compared with HC (P=0.03), but after
adjustment with other covariates no correlations with
parameters of iron status or disease activity were found.
It seems that both hepcidin and prohepcidin offer a major
contribution in the development of anemia in IBD, but their
levels alone seem inadequate for use in distinguishing IDA
from ACD.
4. Erythrocytes parameters
4.1. Red cell distribution width
The red cell distribution width (RDW) is derived from pulse
height analysis and is the width of the red cell size
distribution curve in fL at the 20% level of the peak. The
RDW can also be expressed as the CV% of the measurements
of the red cell volume. It is a quantitative measurement ofvariation in red cell size and is equivalent to anisocytosis
seen on the examination of a stained blood film.78 A
classification of anemia based on MCV and RDW has been
suggested.79 In addition to microcytic, normocytic, and
macrocytic, this classification further divides the RBC
population into homogeneous (with normal RDW) and
heterogeneous (with increased RDW). The former include
hypoproliferative anemia, aplasia, and thalassemia hetero-
zygosis; the latter comprise nutritional anemia such as
deficiencies in iron, B12, and folic acid and sideroblastic
anemia.80 However, an increase in the RDW in patients with
anemia due to chronic infections and at least half of
heterozygotes for thalassemia have been reported, and
normal values of RDW are seen in 15%–20% of IDA.80 Where
microcytosis and macrocytosis exist within the same sample,
the two abnormalities may cancel each other out and cause a
normal MCV, however, the resulting high RDW will identify
the error.78 Moreover, in patients treated with purine
analogs the effect of these drugs on MCV should be taken
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type of patients.
There is a wide distribution of RDW values within a given
disease and this has diminished its usefulness in differential
diagnosis, but its importance as a general marker of
abnormality has been maintained.81 Moreover there are
significant differences on the measurements (CV percentage
or direct measurement) and the reference intervals in the
various methods used for calculation of the RDW.80
The amount of literature concerning the implication of
RDW in the field of IBD is rather limited. Cakal et al. in 200982
found that RDW was significantly elevated in patients with
active IBD compared with those with inactive disease and
controls (Pb0.05). In another retrospective review of 284
patients with IBD,83 there was a significant difference in the
mean RDW between CD and UC (14.9 vs. 14.3, P=0.027),
suggesting RDW as a marker in differentiating CD from UC. In
a study from our group84 RDW was significantly increased in
IBD patients compared with HC, whereas it was positively
correlated with sTfR and negatively with Tsat. Additionally,
RDW was found significantly different in patients with IDA
compared with those without IDA. High RDW (N14) was
among the best markers for diagnosis of IDA with a sensitivity
of 93% and a specificity of 81%. Finally, RDW was not
significantly correlated with disease activity.
4.2. Percentage of hypochromic red cells
Percentage of hypochromic red cells is defined as cells with
intracellular hemoglobin of b28 g/dl.85 In the healthy
population, the percentage of hypochromic red cells does
not exceed 2.5% and values greater than this are indicative of
iron deficient erythropoiesis.86 Percentage of hypochromic
red cells is the concentration of hemoglobin in individual
cells rather than the mean, as happens with mean cell
hemoglobin (MCH) or mean cell hemoglobin concentration
(MCHC). It is a more sensitive marker because small changes
in the number of red cells with inadequate hemoglobin can
be measured before there is any change in the MCHC.78 Some
sophisticated instruments can report this parameter but it
has been argued that, as mature red cells have a longer
lifespan, the percentage of hypochromic red cells integrates
information from over too long a period and may be less
sensitive than reticulocyte hemoglobin in diagnosing func-
tional IDA or monitoring anemia treatment.78 Some studies
report that the percentage of hypochromic red cells is
sensitive enough for the measurement of functional IDA.87
Additionally, the utility of the test is limited as the
percentage of hypochromic red blood cells is dependent on
the total number of red blood cells, which may vary with the
length of storage time. Currently, there are no studies
investigating the role of this parameter in IBD.
4.3. Erythrocyte zinc protoporphyrin
In IDA and lead poisoning, the enzyme ferrochelatase
catalyzes the incorporation of zinc, instead of iron, into
protoporphyrin IX (the immediate precursor of heme),
resulting in the formation of zinc protoporphyrin (ZPP). As
the levels of ZPP reflect iron status in the bone marrow
during erythropoiesis, ZPP values N40 μmol/mol hemoglobinhave been shown to indicate in addition to IDA, its severity as
well and thus distinguish between mild (latent) IDA without
clinical symptoms (ZPP: 40–60 μmol/mol hemoglobin) and
IDA with clinical symptoms (ZPP N80 μmol/mol hemoglo-
bin).45 ZPP is also valuable in the diagnosis of ACD.88
However, as zinc deficiency rather common in inflammatory
disorders,89 the interpretation of ZPP levels should be
handled with caution in the setting of IBD.
5. Reticulocytes parameters
5.1. Mean reticulocyte volume
There is evidence that Mean Reticulocyte Volume (MRV)
increases after iron supplementation therapy in patients
with IDA and decreases with the development of iron
deficient erythropoiesis. The MRV decreases and reticulo-
cytes are smaller than mature red cells following treatment
with vitamin B12 or folate.78 However there are limitations
in the use of MRV since it lacks standardization, which means
numeric results from different manufacturers are not
comparable and there is no quality control material
available.
5.2. Reticulocyte hemoglobin concentration
After the decade of 1990 some new technology hematology
analyzers made possible to measure the hemoglobin con-
centration of reticulocytes (CHr). CHr is measured in the
stained reticulocytes using two angle light scatter. The
reference mean value in healthy population is 30.8 pg, with
the same value in males and females, and the lower limit of
normal is 28 pg.78 The CHr provides an indirect measure of
the functional iron available for new red blood cell
production over the previous 3–4 days and it also provides
an early measure of the response to iron therapy, increasing
within 2–4 days of the initiation of intravenous iron
therapy.78 It is an early indicator of iron-restricted erythro-
poiesis in patients receiving erythropoietin therapy. These
patients may have functional IDA and respond to iron therapy
even with very high serum ferritin values. A value of CHr
b28 pg was found to predict functional IDA more accurately
than ferritin or Tsat.78
Although there are no studies evaluating CHr in patients
with IBD it could be a reliable index for measuring the
response to iron supplementation therapy. Large studies are
needed to confirm this hypothesis in this particular group of
patients.
5.3. Immature reticulocyte fraction
Immature Reticulocyte Fraction (IRF) indicates the less
mature subgroup of reticulocytes, which contain the most
RNA, and is an early and sensitive index of erythropoiesis.90
Immature reticulocytes are released into the peripheral
circulation during periods of intense erythropoietic stimula-
tion such as hemorrhage, certain anemias or in response to
therapy to stimulate bone marrow production.78 The IRF
increases before the total reticulocyte count and has been
found to be useful in distinguishing anemias characterized by
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IRF) from anemias due to reduced marrow activity (low
reticulocytes, low IRF) and from situations such as acute
infections and myelodysplastic syndromes (low/normal re-
ticulocytes, high IRF).80
A recent study, evaluating IRF in IBD patients,84 showed
significantly increased IRF in IBD patients compared to HC
(pb0.0001). IRF was not significantly correlated with
ferritin, Tsat or sTfR and no differences in IRF between
patients with IDA and patients without IDA were found.
Higher IRF in patients compared to HC could be attributed to
an ongoing blood loss in IBD patients, often subclinical, as a
result of chronic inflammation in the gut, thus leading to an
increased “drive” for erythropoiesis in the bone marrow,
even in low iron availability conditions, due to impaired iron
absorption.
Limitations of IRF are the non-standardization, the
reference intervals are method dependent and the sensitiv-
ity is lower in non-fluorescence-based analyzers.80 This
makes IRF a marker of rather limited use in anemia
evaluation in IBD.
5.4. Red blood cell size factor
Red blood cell size factor (RSF) is the result of the square
root of the product of Mean corpuscular volume (MCV)
multiplied by the Mean Reticulocyte Volume (MRV) and
seems to be a suitable parameter for the study of bone
marrow erythropoietic activity, as it provides a very good
level of agreement with reticulocyte hemoglobin content
(CHr). There is evidence of a significant correlation between
RSF and CHr with excellent diagnostic performance of RSF
compared with CHr in diagnosing of the type of anemia.91 A
significant correlation between RSF and reticulocyte hemo-
globin equivalent (Ret He) in the diagnosis of inefficient
erythropoiesis has also been observed.92
RSF was found significantly positively correlated with Tsat
and negatively with sTfR in a recent study of 100 patients
with IBD.84 RSF was significantly lower in patients with IDA
compared with patients with other causes of anemia and
patients without anemia. Low RSF was among the best
markers for diagnosis of ID with a sensitivity of 83% and a
specificity of 82%. On the contrary, concerning disease
activity, RSF was not significantly different between active
and non-active disease and no significant correlation
between RSF and CRP levels was found. Based on these
data RSF seems to be a sensitive real time parameter for the
early detection of the impaired erythropoietic mechanisms
in IBD patients.
5.5. Reticulocyte distribution width
Reticulocyte Distribution Width (RDWR) is a new generation
reticulocyte index, which is automatically reported in the
new technology hematology analyzers. It can be presented as
RDWR-CV (Coefficient of Variation) and RDWR-SD (Standard
Deviation). RDWR-SD is the standard deviation of the retic
volume multiplied by the volume factor and is expressed in
femptoliters (fL). RDWR-CV is the ratio of RDWR-SD and the
retic volume mean (MRV) multiplied by 100 and is expressed
as percentage. Both RDWR-SD and RDWR-CV are derived fromthe reticulocyte histogram. RDWR is an indication of the size
dispersion within the reticulocyte population.93
In a recent study both indices were found to be
significantly increased in patients with CD and UC, compared
to HC (pb0.0001).84 RDWR-CV only was significantly nega-
tively correlated with Tsat and positively with sTfR. In
addition, RDWR-CV was significantly higher in patients with
IDA compared with patients with other causes of anemia and
patients without anemia. The sensitivity of high values of
RDWR-CV for diagnosis of IDA was 60% and the specificity was
51%. It seems that RDWR and reticulocyte number play a
similar role for reticulocytes as RBC count and RDW play for
red blood cells. Both RDWR-SD and RDWR-CV were signifi-
cantly correlated with disease activity and CRP.6. Conclusions
A great challenge for the IBD practitioner is to combine
traditional/conventional anemia markers with the new
generation parameters, in order to achieve the highest
diagnostic yield of anemia, in patients with IBD (Fig. 2).
Anemia is a rather complex manifestation of IBD, due to the
mixed type of IDA and ACD.
From the conventional markers, serum iron remains an
unreliable index for the diagnosis of IDA, because it is
affected by a variety of factors. Ferritin, seems to play a
central role in the definition and diagnosis of anemia in IBD
and, in combination with other parameters, remains a
cornerstone of the diagnosis of IDA, with or without ACD.
TRF is superior to serum iron or Tsat but not better than
ferritin in diagnosis of IDA; however, it can be used with
other markers to detect patients who can profit from
combination therapy with iron and erythropoietin. Tsat is a
classic marker of anemia, giving indirect information of the
extent of iron use in the bone marrow, although it does not
provide information about the condition of iron stores. It is
included in the definition of anemia in IBD, as well as in the
minimum workup, in anemic patients with IBD. sTfR indicate
marrow erythropoietic activity and reflect tissue IDA;
remains useful in the differential diagnosis between IDA
and ACD, but is expensive and not always available.
Iron metabolism regulators, hepcidin and prohepcidin,
are still under investigation for their role in the anemia of
IBD, they seem to play a central role in the development of
it, but they are rather inadequate to distinguish IDA from
ACD.
In the group of erythrocyte parameters, RDW is a classic
and very strong marker for diagnosis of IDA, with good values
of sensitivity and specificity, but not very useful in
differential diagnosis, remaining a rather general marker of
abnormality. Percentage of hypochromic red cells and zinc
protoporphyrin are not validated in patients with IBD, with
the former still being unclear from the supporting literature
whether it is better or worse than CHr in diagnosing
functional IDA. A recently described mathematic model94
suggesting new ways of diagnosing and predicting IDA, with
the use of erythrocyte parameters, could be evaluated in
IBD.
As far as the new generation reticulocytes parameters are
concerned (MRV, CHr, IRF, RSF and RDWR), the literature
about their role in the anemia of IBD is very limited, but some
IBD with anemia
Rule out other causes of 
anemia
Ferritin<30ng/ml
Iron deficiency 
anemia
Ferritin>30-100ng/ml
Anemia of 
chronic disease
Ferritin>100ng/ml
Disease activity, CRP
Tsat<16%
sTfR/log ferritin <1
RDW>14
RSF<98.6 fl 
Figure 2 Algorithm for the differentiation of iron deficiency anemia from anemia of chronic disease in inflammatory bowel disease
(IBD). Tsat, Transferrin saturation; sTfR, soluble transferrin receptor; CRP, C-reactive protein; RDW, red cell distribution width; RSF,
Red blood cell size factor.
389Diagnosing anemia in inflammatory bowel diseaseof them seem very promising in the evaluation of the anemia
in patients with IBD, while others may have a role in
reflecting anemia mechanisms. In any case, large studies are
needed in order to validate them in everyday clinical
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